Status:
COMPLETED
Covid-19 in Lupus Patients
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Systemic Lupus Erythematosus
Covid-19
Eligibility:
All Genders
18-90 years
Brief Summary
The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its effi...
Detailed Description
Introduction:The Covid-19 pandemic has had a major impact on many countries on the sanitary and economic level. Finding an efficient cure is paramount in order to reduce its severity and mortality. Se...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- adult patient with systemic lupus erythematosus seen during the last year in the departments of rheumatology or nephrology
- Exclusion criteria:
- \- patient not speaking french nor english
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04355702
Start Date
March 1 2020
End Date
December 30 2020
Last Update
March 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295